BioSpace News Archive

Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”) today announced the closing of an underwritten public offering in the United States (the “Offering”) of 641,026 American Depositary Shares (“ADSs”), each representing 180 ordinary shares of Bionomics, at a public offering price of US$7.80 per ADS.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022.

Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Skylight Health Group Inc. (TSXV:SLHG; OTCQX: SLHGF) (“Skylight Health” or the “Company”) today announces that the Company has been granted an extension by the TSX Venture Exchange (the “TSXV”) to complete the final tranche of the previously announced US$5 million financing in the form of convertible debentures (“Financing”) by no later than December 21, 2022.

Vial has added NEXT Oncology to their Preferred Site Network (PSN).

Brainstorm Cell Therapeutics is seeking FDA approval of its mesenchymal stem cell therapy called NurOwn for the treatment of ALS.